Content about Zinc gluconate

October 29, 2012
ProPhase rejects second overture from Matrixx Initiatives

ProPhase Labs on Monday again rejected an acquisition proposal from Matrixx Initiatives. Matrixx's latest offer was to acquire ProPhase for $1.60 per share in cash, up from a prior $1.40 per share proposal.

DOYLESTOWN, Pa. — ProPhase Labs on Monday again rejected an acquisition proposal from Matrixx Initiatives. Matrixx's latest offer was to acquire ProPhase for $1.60 per share in cash, up from a prior $1.40 per share proposal. 

September 17, 2012
ProPhase rejects Matrixx acquisition proposal

ProPhase Labs on Monday announced that it rejected an unsolicited, nonbinding proposal from Matrixx Initiatives to acquire the company for $1.40 per share in cash, subject to further due diligence by Matrixx.

DOYLESTOWN, Pa. — ProPhase Labs on Monday announced that it rejected an unsolicited, nonbinding proposal from Matrixx Initiatives to acquire the company for $1.40 per share in cash, subject to further due diligence by Matrixx.

ProPhase stock was up 20 cents to $1.39 in mid-afternoon trading.

Matrixx is the owner of the Zicam brand of cold and allergy products and is a direct competitor to ProPhase's Cold-Eeze Cold Remedy product line.

November 1, 2011
ProPhase launches Cold-Eeze oral spray

ProPhase Labs on Tuesday launched the Cold-Eeze oral spray, which is formulated with zinc gluconate to help reduce the severity and duration of the common cold.

DOYLESTOWN, Pa. — ProPhase Labs on Tuesday launched the Cold-Eeze oral spray, which is formulated with zinc gluconate to help reduce the severity and duration of the common cold.

October 18, 2009
FDA warns, then withdraws letter over combining vitamin C and Vicks cough-cold formulations

Make no mistake, this Food and Drug Administration has shown time and time again this...

NEW YORK Make no mistake, this Food and Drug Administration has shown time and time again this year that it has taken a shoot-first, ask-questions-later approach to ensuring the safety of the products it regulates. The FDA, in a news release, stated that the warning letter was posted due to an internal systems error, and in fact no warning had been sent to Procter & Gamble.

 

Yet. Because the letter was still written, and that fact can’t be explained away by an internal systems error.